Therapeutics: Targeting an oncometabolite

摘要

Specific mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 result in the generation of a particular metabolite - the (R)-enantiomer of 2-hydroxyglutarate ((R)-2HG). The production of high concentrations of (R)-2HG is associated with biological outcomes that promote tumour progression. Thus, there has been considerable interest in developing drugs that target mutant IDH1 and IDH2.